LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $119.23, for a total value of $178,845.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NASDAQ LIVN opened at $120.16 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. LivaNova PLC has a 1 year low of $76.14 and a 1 year high of $131.54. The firm has a market capitalization of $6.11 billion, a P/E ratio of 36.30, a PEG ratio of 3.77 and a beta of 0.94.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The firm had revenue of $272.10 million during the quarter, compared to analyst estimates of $275.03 million. During the same period in the previous year, the company earned $0.83 earnings per share. LivaNova’s revenue was up 8.3% on a year-over-year basis. On average, analysts expect that LivaNova PLC will post 3.1 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. UBS Group AG increased its position in shares of LivaNova by 47.8% in the 1st quarter. UBS Group AG now owns 14,477 shares of the company’s stock valued at $1,281,000 after acquiring an additional 4,683 shares during the period. Royal Bank of Canada increased its position in shares of LivaNova by 1,050.6% in the 1st quarter. Royal Bank of Canada now owns 7,168 shares of the company’s stock valued at $634,000 after acquiring an additional 6,545 shares during the period. Principal Financial Group Inc. increased its position in shares of LivaNova by 3.0% in the 1st quarter. Principal Financial Group Inc. now owns 191,925 shares of the company’s stock valued at $16,985,000 after acquiring an additional 5,532 shares during the period. Allianz Asset Management GmbH increased its position in shares of LivaNova by 534.7% in the 1st quarter. Allianz Asset Management GmbH now owns 105,654 shares of the company’s stock valued at $9,351,000 after acquiring an additional 89,009 shares during the period. Finally, Bank of Montreal Can increased its position in shares of LivaNova by 15.2% in the 2nd quarter. Bank of Montreal Can now owns 4,411 shares of the company’s stock valued at $441,000 after acquiring an additional 582 shares during the period. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently commented on LIVN shares. Stifel Nicolaus increased their price objective on LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, July 24th. BidaskClub upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 26th. Needham & Company LLC reiterated a “buy” rating and set a $135.00 price objective (up previously from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. Zacks Investment Research lowered LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Finally, Jefferies Financial Group increased their price objective on LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company. LivaNova presently has a consensus rating of “Buy” and a consensus price target of $126.50.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/11/20/david-s-wise-sells-1500-shares-of-livanova-plc-livn-stock-2.html.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Further Reading: Investing strategies using the yield curve

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.